1. Scrip
  2. >>Business
  3. >>Deals

Ferring Leapfrogs Into Late-Stage Microbiome Race With Rebiotix Buy

 
• By Jessica Merrill

The Swiss specialty drug company gains a Phase III microbiome product for the prevention of recurrent Clostridium difficile infection and a broader platform for Microbiota Restoration Therapy.

Handshake of businessmen

Ferring Pharmaceuticals AS is taking a big leap into the forefront of the microbiome drug development space with the proposed acquisition of Rebiotix Inc.. The Swiss specialty pharma announced plans to buy Roseville, Minn.-based Rebiotix April 5 for an undisclosed sum, gaining a Phase III treatment for recurrent Clostridium difficile infection (CDI) that is a contender to be the first approved human microbiome product.

Rebiotix's RBX2660 is in Phase III testing for the prevention of recurrent CDI, and the company also has a pipeline...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Glenmark Fortifying Branded Play, Shifts Focus To High Margin Products

 
• By Anju Ghangurde

Glenmark signals thrust on high margin products, while exiting tail end brands as part of efforts to emerge as a branded company. In-licensed assets like Brukinsa and Tevimbra are seen as pivotal to driving growth alongside.

China-Originated Assets Lead Global GLP-1 Deals

 
• By Xu Hu

The total deal value of GLP-1-associated assets globally this year is already double that of the previous two years combined, with China-originated assets accounting for a substantial majority.

Boehringer Expands Eyecare Horizons With Palatin Collaboration

 
• By Andrew McConaghie

The German company already had four eye disease candidates in Phase II development and sees promise in Palatin’s novel melanocortin receptor modulators.

Skyhawk Flies High With Another Big Pharma, Getting Up To $2bn In Merck KGaA Deal

 
• By Mandy Jackson

Deal Snapshot: Skyhawk raised its first seed funding in 2018 and has funded its operations primarily through partnering fees to date, including its latest agreement with Merck KGaA.

More from Business

Boehringer Expands Eyecare Horizons With Palatin Collaboration

 
• By Andrew McConaghie

The German company already had four eye disease candidates in Phase II development and sees promise in Palatin’s novel melanocortin receptor modulators.

Egetis Eyes Swift US Submission For Emcitate

 
• By Kevin Grogan

The Sweden-based firm is set for talks with the FDA on the regulatory path for its MCT8 deficiency candidate.

Stock Watch: Pfizer Relights Q2 Earnings Season’s Fire

 
• By Andy Smith

Pfizer showed how to come out on top with investors during earnings season. Post strong sales growth – and avoid mentioning tariffs, most favored nation pricing or Medicare modernization impacts.